ABSTRACT
Background In the last decade, the rates of infectious syphilis have increased by 505% in Ontario, Canada. Underserved populations–people who use drugs, un(der)housed individuals, and those living in rural and remote areas - face unique social and healthcare challenges that increase their vulnerability to syphilis infections and hinder their access to timely diagnosis and treatment. Given the shift in epidemiology and the geographic disparities in resources, there is no one-size-fits-all solution to this complex issue. Access to low-barrier diagnostics, such as point-of-care (POC) tests for HIV and hepatitis C, has been shown to be an effective strategy for reaching underserved people outside of traditional healthcare settings. However, there is a paucity of evidence regarding the effectiveness of POC tests for other sexually transmitted and blood-borne infections, particularly in non-urban, rural, and remote settings.
Methods/Design The Syphilis Rapid Point-of-Care Testing and Immediate Treatment Evaluation (SPRITE) Study includes nine Public Health Units (PHUs) in Ontario. The INSTI® Multiplex HIV-1/HIV-2/Syphilis Antibody Test will be used to evaluate a “rapid test and immediate treatment” outreach model of care targeting people who are un(der)housed or who use drugs at multiple community-based settings anchored to their respective PHU. Implementation of the model of care will be evaluated using the Reach, Effectiveness, Adoption, Implementation, and Maintenance (RE-AIM) Framework, following a community-based participatory approach. Empirical results will inform network models to estimate the population-level impact of using POC test to curb transmission.
Discussion Urgent, tailored, and equitable action is needed to address the alarming rise in syphilis rates in Canada. This study assesses the real-world effectiveness of syphilis POC tests in breaking barriers and bringing services to the population at the highest risk. Results will inform future implementation, build capacity, and provide the evidence necessary for program decision-making.
STRENGTHS AND LIMITATIONS OF THIS STUDY
This study employs a comprehensive evaluation framework, utilizing various approaches and tools encompassing quantitative and qualitative methods to address our research questions. This multiplicity enables enhanced triangulation of research findings.
Including various public health units addresses a gap in research by acknowledging and investigating the unique challenges faced by underserved communities living in diverse non-urban, rural, and remote settings.
Leveraging academic, public health, and community partnerships enhances this study’s potential for real-world impact by incorporating diverse perspectives, expertise, and collaborative efforts.
Competing Interest Statement
SS has a perceived conflict of interest; she received an honorarium from Novo Nordisk as an advisory board member (unrelated to this study). All other authors declare: no support from any organisation for the submitted work; no financial relationships with any organisations that might have an interest in the submitted work in the previous three years; no other relationships or activities that could appear to have influenced the submitted work.
Funding Statement
This work was supported by the Canadian Institutes of Health Research (CIHR) through a Catalyst (SR8 190795), Operating (AS1-192619), and Knowledge Mobilization (EKS 193138) granted to the NPA SS. The team gratefully acknowledges funding received from PHO through the Locally Driven Collaborative Projects program granted to NPA MC. The views expressed in this publication are the views of the project team and do not necessarily reflect those of Public Health Ontario or CIHR. SPRITE team would also like to thank Public Health Ontario (PHO) for its support of this project. POB would like to acknowledge funding from the Ontario HIV Treatment Network, Public Health Ontario, Canadian Institutes of Health Research, the National Microbiology Laboratory, and Health Canada.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
The Health Sciences and Affiliated Teaching Hospitals Research Ethics Board (HSREB) at Queen's University gave ethical approval for this work.
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Yes
Data Availability
N/A- the study is still in the data collection phase.
